A carregar...
Bardoxolone Brings Nrf2-Based Therapies to Light
The targeted activation of nuclear factor erythroid-derived-2-like 2 (Nrf2) to alleviate symptoms of chronic kidney disease has recently garnered much attention. Unfortunately, the greatest clinical success to date, bardoxolone, failed in phase III clinical trial for unspecified safety reasons. The...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Mary Ann Liebert, Inc.
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3704121/ https://ncbi.nlm.nih.gov/pubmed/23227819 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/ars.2012.5118 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|